Amgen’s Stelara Biosimilar Produces Positive Phase III Results
Firm’s ABP 654 Ustekinumab Candidate Is Also Being Lined Up For Interchangeability
Amgen has reported positive preliminary results from a Phase III study for its ABP 654 proposed ustekinumab biosimilar rival to Stelara, for which the firm also intends to pursue an interchangeability designation.
